Biotechnology in the Heart of the Capital City

CSL Behring is a global leader in developing and delivering high-quality medicines that treat people with rare and serious diseases. Our treatments offer promise for people in more than 100 countries.

Find our more about our company

CSL Behring News

CSL Behring News

Call to action to meet our experts at Swiss Biotech Day 2024

Elevating Biotech Horizons: CSL at Swiss Biotech Day 2024

Shaping the future of healthcare

05 Apr 2024
Winners Biomedical Science Award 2024

Commitment to young researchers and the environment

Biomedical Science Award and Bernese Environmental Research Award

25 Mar 2024
Visit-Minister

High-ranking visit to Bern

CSL Behring hosts Federal Councillor and Moroccan Trade Minister.

07 Mar 2024
RareDiseaseDay-2024

Bern lights up on Rare Disease Day

On 29 February, the Burgerspital Bern lit up in the colours of Rare Disease Day.

04 Mar 2024
RDD - Bern

Rare are many

The contribution of R&D

28 Feb 2024
HY-Results_EN

Half Year Results 2023/2024

CSL reported net income after tax of $2.02 billion in the first half of 2024.

13 Feb 2024
Rare Disease Day 2024

Let's Shine a Light on Rare Diseases

On 29 February 2024, the Rare Disease Day will take place.

08 Feb 2024
visit-botschaft

Diplomatic visit to CSL Behring in Bern

As part of a visit to the cantonal government, a visit to CSL Behring in Bern was also on the agenda.

25 Jan 2024
hemgenix

Swissmedic Approval for HEMGENIX®

Swissmedic Authorises CSL’s HEMGENIX® as First Gene Therapy for Hemophilia B

15 Jan 2024
Load more